Can bimekizumab be stopped after use?

Bimekizumab is a new type of immunotherapy drug mainly used to treat psoriasis and other immune-mediated diseases. It is a monoclonal antibody targeting IL-17A and IL-17F. It reduces the excessive response of the immune system and reduces the inflammatory response by inhibiting these two cytokines. Bicizumab has shown significant efficacy in the treatment of psoriasis, but whether patients can discontinue the drug after using it for a period of time depends on several factors.

The therapeutic effects of bicizumab usually appear within a few weeks, and many patients experience significant improvements early in treatment. However, whether the drug can be discontinued does not entirely depend on the efficacy of the drug itself, but is closely related to the patient's individual condition, the severity of the condition, and the response during treatment. For patients with psoriasis, treatment usually requires long-term maintenance because psoriasis is a chronic disease and tends to relapse. Therefore, even if the symptoms are relieved during initial treatment, the medication cannot be stopped hastily.

Generally speaking, in the early stages after starting treatment, doctors may recommend that patients continue maintenance treatment, usually for several months or for an extended period of time, with adjustments based on treatment response. Bicizumab treatment regimens typically include an initial phase of frequent injections, followed by a gradual reduction in frequency, and finally a maintenance phase. The goal of this regimen is to help patients maintain efficacy and reduce disease recurrence.

The timing of drug withdrawal should be determined by a professional doctor based on the patient's condition and treatment response. If a patient's symptoms are under control and there are no signs of disease recurrence during maintenance treatment, the doctor may recommend reducing the frequency of use of the drug or even considering discontinuing the drug. However, after stopping the drug, patients still need to monitor their condition closely to prevent recurrence.

Reference materials:https://www.drugs.com/bimekizumab.html